Update on hormone therapy

• 1. Manage a newly menopausal woman’s • 3. Understand the data in the most recent paper from WHI on breast cancer and combined HT The WHO Terminology for Adverse Event Rates
1 to 10/10,000
Council for International Organizations of Medical Sciences (CIOMS).
Guidelines for preparing core clinical-safety information on drugs. 2nd edition. Geneva:CIOMS: 1998 • 52 year old healthy female complains of severe flushes, feels that she is waking 12 times thru the night and is frequently drenched at work • Has tried a supplement of clover and black cohosh, silken tofu, progesterone cream and meditation • She exercises regularly and has read about layering her clothes, stopped hot drinks, spicy foods and wine • Venlafaxine(Effexor) XR 37.5-75 mg OD • Gabapentin 300 mg HS to start then tid if tolerated (alternate Lyrica 50mg am 25 HS) • Progestin only: MPA( Provera) 20-30 mg 5 extra CHD
• How does this affect the counselling? • Estradiol 1 mg oral/ 50 patch/2 squirts • (no longer have E1 Ogen)• If there is a uterus need Prometrium 200 mg HS/Provera 2.5mg/or norethindrone acetate 0.35mg(Micronor) daily or Mirena • If there are fibroids or a very big woman or high risk for hyperplasia might start cyclically to minimize biopsy repeats for persistent bleeding • Specific timelines gone- no longer less than 5 years- with adequate risk benefit counselling and if symptomatic can continue to treat.
• Patient and caregiver often try to reduce dose • Sometimes get spotting with dose reduction and still need to see them for it-ET or Bx if able • Absolutely no need to stop early menopause • Tried to stop HT after a new article in the • What are the risks of starting at 62 ? • 1 extra CHD
• 9 extra CVA
• 16 extra VTE
• 8 extra Br Ca
• 5 extra Deaths
• 19 extra CVA
8 extra VTE
• 1 extra CHD 4 less
• 9 extra CVA 19 extra
• 16 extra VTE 8 extra
• 8 extra Br Ca 10 less
• 5 extra Deaths same
Step Down the Dose if able since risks are assumed to be less with lower dose- not a lot of good evidence though • Good time to try low dose- might have • Estradiol 0.5mg/ patch 25 or 35/ gel 1 • Breast cancer mortality reported in E&P • Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women JAMA v305 no 15 p1684-92 Differences Between the Observational Nurses Mean age or age range at enrollment
Smokers (past and current)
BMI (mean)
25.1 kg/m2
28.5 kg/m2*
Aspirin users
HRT regimen
Menopausal symptoms (flushing)
*34.1% had BMI 30 kg/m2
Grodstein et al. Ann Intern Med 200;133:933-41. Writing Group for the WHI Investigators. JAMA 2002;288:321-33.
hysterectomy randomly assigned to E&P followed after trial completed in 83% had new consent • Mean intervention time of 5.6(SD 1.4) • E&P was associated with more invasive • Br Ca in E&P were similar in histology and grade to placebo Br ca cases but were more likely to be node positive • 25 deaths (0.03% per year) vs 12 deaths • HR 1.96 ( 95% CI 1-4.04) as well as more deaths from all causes after a diagnosis of Br ca (51 vs 31) • From observational trials most but not all breast cancers associated with combined hormone therapy have favourable characteristics less advanced stage and less mortality risk • For women entering the study with no prior hormone use the HR for Br Ca was 1.16 (95% CI .98-1.37) • compared to 1.85 (1.25-2.80) for women • Increased risk of Br Ca on combined E&P hormone therapy is the same risk women assume if they consume alcohol, fail to exercise regularly or become overweight after menopause.
• Need to promote high quality women’s health with up to date risk benefit information • The level of increased risk is defined as • A rare risk according to WHO classification of adverse events with 8 additional breast cancer cases detected among 10,000 women on combined therapy • 1.3 additional deaths per 10,000 women for combination hormone therapy users in WHI • In Million Women observational study combined HT was associated with higher Br Ca mortality HR 1.22 ( 95% CI 1.00-1.48) p=0.05 • From 50-59 years 5/1000 women currently die of Br Ca while 55 die of other causes • From 60-69 7/1000 women currently die • From 70-79 9/1000 deaths of Br Ca while • From 80-89 11/1000 deaths of Br Ca while

Source: http://obstetrics.medicine.dal.ca/news/documents/UpdateonHormoneTherapy-2011.pdf

013955 1.4

FACHINFORMATION (ZUSAMMENFASSUNG DER MERKMALE DES ARZNEIMITTELS)gerschaft wird empfohlen. Zyklusstörungenwie Oligomenorrhö oder Amenorrhö sollenvor der ersten Verschreibung abgeklärtwerden. Die Häufigkeit der Kontrollunter-suchungen ist individuell verschieden, unddie Möglichkeit der Beeinflussung laten-Jede Tablette enthält 75 Mikrogramm Deso-ter oder manifester Erkrankungen (sieh

Microsoft word - stm kilimanjaro guide.docx

RIGHTFOOT , The Brewery Business Centre, Bells Yew Green, Frant, East Sussex TN3 9BD E. ben@rightfoot-uk.com P. +44 (0)1892 750900 www .rightfoot-uk.com Kit-List When preparing for Kilimanjaro, there is a difficult balance to strike between packing enough so that you have all you need, and packing too much and therefore carrying too much weight. Bear in mind in particular that th

© 2010-2017 Pharmacy Pills Pdf